Tumor expression of miR-34a-3p is an independent predictor of
recurrence in non-muscle-invasive bladder cancer and promising
additional factor to improve predictive value of EORTC nomogram

J 2019

Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram

JURÁČEK, Jaroslav; M. STANIK; Petra VESELÁ; Lenka RADOVÁ; J. DOLEZEL et al.

Základní údaje

Originální název

Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram

Autoři

JURÁČEK, Jaroslav; M. STANIK; Petra VESELÁ ; Lenka RADOVÁ; J. DOLEZEL; M. SVOBODA a Ondřej SLABÝ

Vydání

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, New York, ELSEVIER SCIENCE INC. 2019, 1078-1439

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.882

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/19:00108457

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

Non-muscle invasive bladder cancer; Recurrence; microRNA; miR-34-3p

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 3. 2020 22:00, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Objectives: Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease characterized by a high primary tumor recurrence rate. Current prognostic systems used for predicting recurrence in individual patients have limitations and do not consider the biological background of this tumor type. Our study aimed to find microRNAs (miRNAs) associated with NMIBC recurrence. Methods: Seventy-eight NMIBC patients were prospectively enrolled and divided into exploratory and validation cohorts. Out of these patients, 32 developed recurrence within 18 months after surgery, while 46 did not show any sign of recurrence after 30 months. Expression profiles of 2,578 miRNAs were obtained using Affymetrix miRNA microarrays and candidate miRNAs validated using the individual quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Results: The expression profiling revealed a set of 137 miRNAs differentially expressed between NMIBC patients with and without recurrence (P < 0.05). In the validation phase, miR-34a-3p had a significantly higher expression in tumors of NMIBC patients without recurrence (P = 0.0155). Decreased expression of miR-34a-3p was associated with significantly shorter recurrence-free survival (P = 0.009). Cox regression analysis confirmed that miR-34a-3p is an independent biomarker associated with a lower risk of recurrence (hazard ratio (HR) = 0.3184, 95% confidence interval = 0.003-0.681, P = 0.0258). Combination of miR-34a-3p and European Organization for Research and Treatment of Cancer risk score into one predictive model enabled to predict individual risk of recurrence with high statistical significance and analytical performance (P < 0.0001; area under curve = 0.8368; sensitivity 83%, and specificity 75%). Conclusions: Our data suggest that miR-34a-3p is an independent biomarker of NMIBC recurrence and a promising candidate for further independent validations as an additional factor to improve predictive value of European Organization for Research and Treatment of Cancer nomogram. (C) 2018 Elsevier Inc. All rights reserved.

Návaznosti

NV15-31071A, projekt VaV

Název: Studium močových/tkáňových mikroRNA jako potenciálních biomarkerů uroteliálního karcinomu močového měchýře

Citovat

JURÁČEK, Jaroslav; M. STANIK; Petra VESELÁ; Lenka RADOVÁ; J. DOLEZEL; M. SVOBODA a Ondřej SLABÝ. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2019, roč. 37, č. 3, s. 1-7. ISSN 1078-1439. Dostupné z: https://doi.org/10.1016/j.urolonc.2018.10.014.

@article{1508877,
   author = {Juráček, Jaroslav and Stanik, M. and Veselá, Petra and Radová, Lenka and Dolezel, J. and Svoboda, M. and Slabý, Ondřej},
   article_location = {New York},
   article_number = {3},
   doi = {https://doi.org/10.1016/j.urolonc.2018.10.014},
   keywords = {Non-muscle invasive bladder cancer; Recurrence; microRNA; miR-34-3p},
   language = {eng},
   issn = {1078-1439},
   journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
   title = {Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram},
   url = {http://dx.doi.org/10.1016/j.urolonc.2018.10.014},
   volume = {37},
   year = {2019}
}

TY  - JOUR
ID  - 1508877
AU  - Juráček, Jaroslav - Stanik, M. - Veselá, Petra - Radová, Lenka - Dolezel, J. - Svoboda, M. - Slabý, Ondřej
PY  - 2019
TI  - Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram
JF  - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL  - 37
IS  - 3
SP  - 1-7
EP  - 1-7
PB  - ELSEVIER SCIENCE INC.
SN  - 10781439
KW  - Non-muscle invasive bladder cancer
KW  - Recurrence
KW  - microRNA
KW  - miR-34-3p
UR  - http://dx.doi.org/10.1016/j.urolonc.2018.10.014
L2  - http://dx.doi.org/10.1016/j.urolonc.2018.10.014
N2  - Objectives: Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease characterized by a high primary tumor recurrence rate. Current prognostic systems used for predicting recurrence in individual patients have limitations and do not consider the biological background of this tumor type. Our study aimed to find microRNAs (miRNAs) associated with NMIBC recurrence. Methods: Seventy-eight NMIBC patients were prospectively enrolled and divided into exploratory and validation cohorts. Out of these patients, 32 developed recurrence within 18 months after surgery, while 46 did not show any sign of recurrence after 30 months. Expression profiles of 2,578 miRNAs were obtained using Affymetrix miRNA microarrays and candidate miRNAs validated using the individual quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Results: The expression profiling revealed a set of 137 miRNAs differentially expressed between NMIBC patients with and without recurrence (P < 0.05). In the validation phase, miR-34a-3p had a significantly higher expression in tumors of NMIBC patients without recurrence (P = 0.0155). Decreased expression of miR-34a-3p was associated with significantly shorter recurrence-free survival (P = 0.009). Cox regression analysis confirmed that miR-34a-3p is an independent biomarker associated with a lower risk of recurrence (hazard ratio (HR) = 0.3184, 95% confidence interval = 0.003-0.681, P = 0.0258). Combination of miR-34a-3p and European Organization for Research and Treatment of Cancer risk score into one predictive model enabled to predict individual risk of recurrence with high statistical significance and analytical performance (P < 0.0001; area under curve = 0.8368; sensitivity 83%, and specificity 75%). Conclusions: Our data suggest that miR-34a-3p is an independent biomarker of NMIBC recurrence and a promising candidate for further independent validations as an additional factor to improve predictive value of European Organization for Research and Treatment of Cancer nomogram. (C) 2018 Elsevier Inc. All rights reserved.
ER  -

JURÁČEK, Jaroslav; M. STANIK; Petra VESELÁ; Lenka RADOVÁ; J. DOLEZEL; M. SVOBODA a Ondřej SLABÝ. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2019, roč.~37, č.~3, s.~1-7. ISSN~1078-1439. Dostupné z: https://doi.org/10.1016/j.urolonc.2018.10.014.

Přehled o publikaci